GTHX

G1 Therapeutics Starts Mid-Stage Bladder Cancer Trial With Cosela

G1 Therapeutics Presents Phase 1 Data at ASCO Describing Favorable Safety Profile and Evidence of Antitumor Activity of Rintodestrant Combined with Palbociclib in Patients with ER+/HER2- Advanced Breast Cancer

G1 Therapeutics Presents Data on COSELA™ (trilaciclib) at ASCO on Potential Immune Activation in Patients with Newly Diagnosed Extensive-Stage Small Cell Lung Cancer

G1 Therapeutics Announces Upcoming Data at the American Society of Clinical Oncology (ASCO) Virtual 2021 Annual Meeting

G1 Therapeutics Presents Two Posters at ISPOR Describing the Estimated Economic Impact of Treating Myelosuppression Among Patients with Extensive-Stage Small Cell Lung Cancer

G1 Therapeutics Initiates Randomized Double Blind Placebo Controlled Phase 2 Study of COSELA™ (trilaciclib) in Non-Small Cell Lung Cancer (PRESERVE 4)

GTHX Stock: 10.22% Increase (From $19.77 To $21.79) Pre-Market Explanation